Pieris Pharmaceuticals, Inc. (PIRS)
Pieris Pharmaceuticals, Inc.
225 Franklin Street
26th Floor
Boston, MA 02110
United States
857 246 8998
https://www.pieris.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 46
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Stephen S. Yoder J.D. | CEO, President & Director | 744.13k | N/D | 1976 |
| Mr. Thomas Bures | Senior VP, CFO & Treasurer | 487.5k | N/D | 1975 |
| Dr. Shane Olwill Ph.D. | Senior VP & Chief Development Officer | 463.91k | N/D | 1976 |
| Maria Kelman | Executive Director of Investor Relations | N/D | N/D | N/D |
| Mr. Prompong Chaikul | Chief Supply Chain Officer | N/D | N/D | 1987 |
| Dr. Florian Witte Ph.D. | VP and Head of Alliance Management & Early Project Leadership | N/D | N/D | N/D |
Descripción
Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Pieris Pharmaceuticals, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
